- Home
- LPCN vs EVAX Comparison
LPCN vs EVAX Comparison
Compare LPCN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- EVAX
- Stock Information
- Founded
- LPCN 1997
- EVAX 2008
- Country
- LPCN United States
- EVAX Denmark
- Employees
- LPCN N/A
- EVAX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPCN Health Care
- EVAX Health Care
- Exchange
- LPCN Nasdaq
- EVAX Nasdaq
- Market Cap
- LPCN 18.2M
- EVAX 17.8M
- IPO Year
- LPCN N/A
- EVAX 2021
- Fundamental
- Price
- LPCN $2.60
- EVAX $5.76
- Analyst Decision
- LPCN Strong Buy
- EVAX Strong Buy
- Analyst Count
- LPCN 1
- EVAX 3
- Target Price
- LPCN $8.00
- EVAX $12.33
- AVG Volume (30 Days)
- LPCN 59.9K
- EVAX 831.7K
- Earning Date
- LPCN 11-07-2025
- EVAX 11-07-2025
- Dividend Yield
- LPCN N/A
- EVAX N/A
- EPS Growth
- LPCN N/A
- EVAX N/A
- EPS
- LPCN N/A
- EVAX N/A
- Revenue
- LPCN $4,208,119.00
- EVAX $3,176,000.00
- Revenue This Year
- LPCN N/A
- EVAX $129.34
- Revenue Next Year
- LPCN N/A
- EVAX N/A
- P/E Ratio
- LPCN N/A
- EVAX N/A
- Revenue Growth
- LPCN N/A
- EVAX 1042.45
- 52 Week Low
- LPCN $2.57
- EVAX $1.20
- 52 Week High
- LPCN $6.17
- EVAX $14.81
- Technical
- Relative Strength Index (RSI)
- LPCN 32.60
- EVAX 49.63
- Support Level
- LPCN $2.75
- EVAX $5.29
- Resistance Level
- LPCN $2.92
- EVAX $6.82
- Average True Range (ATR)
- LPCN 0.14
- EVAX 1.27
- MACD
- LPCN -0.05
- EVAX -0.29
- Stochastic Oscillator
- LPCN 4.69
- EVAX 6.85
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.